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Obesity Is Associated With Increased
Levels of Circulating Hepatocyte Growth Factor
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Catharine A. Slavens, BS,* RoseMarie Jones, MD,§ Keith L. March, MD, PHD, FACC*‡
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OBJECTIVES This study evaluated whether obesity in humans was associated with an increase in circulating
hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) levels.
BACKGROUND Obesity acts as a cardiovascular risk factor by mechanisms that are not fully understood.
Adipose tissue is able to secrete multiple cytokines and growth factors ex vivo. We
hypothesized that the increased presence of adipose tissue in obese subjects results in systemic
elevations of the mitogenic factors HGF and VEGF.
METHODS Blood samples were obtained from lean (n 21) and obese (n 44) volunteers. Serum HGF
and VEGF levels were assessed by enzyme-linked immunoadsorbent assay. Insulin and
fasting glucose levels were measured to evaluate insulin sensitivity. Conditioned medium of
adipose cells was assayed for HGF secretion.
RESULTS Serum HGF levels in obese subjects were more than three-fold higher than those of lean
subjects (2,462  184 pg/ml vs. 765  48 pg/ml, p  0.0001). The VEGF levels were not
significantly elevated in obese subjects (135  31 pg/ml vs. 128  37 pg/ml). The HGF
concentrations, but not VEGF concentrations, were significantly correlated with body mass
index (BMI) (p 0.0001, r 0.74). The observed increases in HGF concentrations of obese
subjects were not secondary to insulin resistance or hypertension. Freshly isolated human
adipose cells secreted HGF.
CONCLUSIONS Our results indicate that obesity is associated with a marked increase in circulating HGF
levels, which correlate linearly with BMI. Because vascular growth factors have been
associated with the pathogenesis of atherosclerosis, the possible role of such humoral factors
as a link between obesity and cardiovascular disease is very intriguing. (J Am Coll Cardiol
2003;41:1408–13) © 2003 by the American College of Cardiology Foundation
Multiple epidemiologic studies have shown that obesity
markedly increases the risk of cardiovascular morbidity and
mortality and is a significant risk factor for coronary artery
disease and congestive heart failure (1–3). A recent study
demonstrated that obesity promotes atherosclerosis even in
adolescent and young adult men (4). This cardiovascular
risk of obesity is in part mediated by the increased preva-
lence of risk factors such as hypertension or insulin resis-
tance, which are frequently associated with obesity (5). This
combination of obesity and cardiovascular risk factors is
commonly referred to as Syndrome X or metabolic syn-
drome. However, in addition to influencing other risk
factors, obesity also acts as a cardiovascular risk factor,
independent of changes in blood pressure (BP), insulin
resistance, or cholesterol levels (1,6). While the hemody-
namic changes associated with obesity are thought to
contribute to the ventricular dysfunction observed in obese
patients (7), less is known about the independent mecha-
nisms by which obesity promotes atherosclerosis.
The adipose tissue is now recognized as an endocrine
organ that secretes multiple cytokines and growth factors
(8,9). Vascular endothelial growth factor (VEGF), for
example, is an angiogenic growth factor which is secreted by
rat adipose tissue ex vivo (10). It has also been found to
cause progression of atherosclerosis, presumably by promot-
ing endothelial proliferation and neovascularization in the
atherosclerotic plaque (11). Hepatocyte growth factor
(HGF) is another endothelial growth factor with potent
angiogenic and mitogenic effects (12,13) that can synergis-
tically augment the angiogenic effects of VEGF in vivo and
in vitro (14). Serum HGF levels are elevated not only in
patients with hepatic disease (15), malignancies (16), or
end-stage renal disease (17), but also in patients with
atherosclerosis and proliferative diabetic retinopathy (18–
20). It has also been shown that the 3T3-L1 adipocyte cell
line can secrete HGF in vitro (21), thus suggesting that
primary adipocytes may also be able to synthesize and
secrete HGF in vivo.
We hypothesized that the increased presence of secretory
adipose tissue in obese subjects would result in systemic
elevations of the angiogenic factors VEGF and HGF.
Therefore, we studied the serum levels of VEGF and HGF
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in lean and obese subjects. Because obesity is frequently
associated with insulin resistance and hypertension (5,22),
we also examined whether the postulated obesity-related
increases in growth factor concentrations were independent
of these comorbidities.
METHODS
Patient selection and characteristics. Blood samples were
obtained from healthy lean subjects (body mass index
[BMI] 25 kg/m2; n  21) or obese subjects (BMI 35
kg/m2; n  44) undergoing bariatric surgical procedures or
outpatient adipose tissue biopsies. Blood samples were taken
in the morning before surgery after an overnight fast, and
serum was separated after coagulation. Blood pressures and
liver function tests (LFT) comprised of serum glutamic-
pyruvic transaminase and serum glutamic-oxaloacetic
transaminase measurements were obtained on most subjects
at the time of blood collection. Systolic blood pressure
(SBP) 140 mm Hg or diastolic blood pressure (DBP)
90 mm Hg at the time of blood draw were considered
elevated. The LFT were elevated if either serum glutamic-
oxaloacetic transaminase or serum glutamic-pyruvic transami-
nase levels were 50 IU/l. No subjects had any known acute
infectious process at the time of enrollment in the study. The
protocol was approved by the Institutional Review Boards of
Indiana University–Purdue University at Indianapolis and St.
Vincent’s Hospital. All subjects provided informed consent.
Insulin resistance. Fasting serum insulin was quantitated
by radioimmunoassay (Linco Research, St. Charles, Mis-
souri), and glucose was determined using a YSI 2300 STAT
plus glucose analyzer (YSI Inc., Yellow Springs, Ohio). The
Homeostatic Model Assessment (HOMA) score, as a
surrogate measure of insulin resistance (23) was calculated
as: fasting insulin (U/ml) fasting glucose (mmol/l)/22.5,
to determine the degree of insulin resistance. For analysis of
insulin resistance effects on HGF levels, obese subjects were
subdivided into three groups according to their degree of
insulin resistance using the HOMA score: 1) obese normal
(HOMA 3, n  13); 2) obese with moderate resistance
(3  HOMA  5, n  11); and 3) obese with severe
resistance (HOMA 5, n  20).
Serum HGF and VEGF level determination. Serum
HGF and VEGF levels were determined by using the HGF
Quantikine ELISA kit and the VEGF Multi-Analyte
Profiting kit (both R&D Systems, Minneapolis, Minnesota)
according to the manufacturer’s instructions. Circulating
HGF levels were assayed in all subjects (n  65); VEGF
levels were obtained in 61 of the 65 subjects. Data are
presented in pg/ml as mean  SEM.
HGF expression by human adipose tissue ex vivo.
Adipocytes and adipose stromal cells (ASC) were obtained
by collagenase digestion of human subcutaneous adipose
tissue samples and separation of the cells by centrifugation
of the tissue samples as described (24). The HGF messenger
ribonucleic acid in tissues and cells was determined by
reverse transcription-polymerase chain reaction using re-
agents from Applied Biosystems (Foster City, California).
Ribonucleic acid was isolated by standard techniques (25),
and 2 g was reverse transcribed for 60 min. The reverse
transcription reaction was split in half for amplification of
HGF and glyceraldehyde-3-phosphate dehydrogenase. The
polymerase chain reaction conditions were 95°  30 s, 55°
 30 s, and 72°  60 s for 35 cycles. Upstream primer for
HGF was 5-ATGTGGGTGACCAAACTCCTG-3,
and downstream primer was 5-CTATTGAAGGGGA-
ACCAGAGG-3 based on Genebank sequence
XM_052253. The primers for HGF span an intron located
between bases 122 and 123 of the complementary deoxyri-
bonucleic acid sequence, therefore eliminating amplification
of genomic deoxyribonucleic acid in the ribonucleic acid
preparation. Primers for human glyceraldehyde-3-
phosphate dehydrogenase were from Applied Biosystems.
To assess secretion of HGF by cultured cells, freshly
isolated adipocytes and ASC were each cultured in Dulbec-
co’s modified Eagle medium with 10% fetal bovine serum
for 48 h. Human aortic endothelial cells (Clonetics, Walk-
ersville, Maryland) were cultured in endothelial basal
media-2 (EBM-2, Clonetics) with 5% fetal bovine serum.
Neither Dulbecco’s modified Eagle medium with 10% fetal
bovine serum nor EBM-2 with 5% fetal bovine serum had
detectable endogenous HGF. The conditioned medium
from each sample was collected and assayed for HGF using
enzyme-linked immunoadsorbent assay.
Statistical analysis. To determine lean versus obese group
differences, the data were analyzed by Fisher exact test for
categorical variables and the t test for continuous variables.
The t test correction for unequal variances was used
where necessary. A one-way analysis of variance was
performed for the comparison of more than two groups.
Linear regression analysis was used to evaluate for a
correlation between growth factor levels and BMI or
HOMA score. The log of the HOMA score was used to
provide a normal distribution for this variable. There was
no difference in the linear regression statistics using the
log of the HOMA score instead of the HOMA score. For
all analyses, a value of p  0.05 was considered not
significant (NS).
Abbreviations and Acronyms
ASC  adipose stromal cells
BMI  body mass index
BP  blood pressure
DBP  diastolic blood pressure
HGF  hepatocyte growth factor
HOMA  Homeostatic Model Assessment
LFT  liver function tests
SBP  systolic blood pressure
VEGF  vascular endothelial growth factor
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RESULTS
Patient characteristics. There was no significant difference
between the lean and obese subject groups in terms of their
age or gender distribution (Table 1). Only two subjects in
each group had elevated LFT. By design, the BMI was
significantly higher in the obese group. As expected from
published data (5,22), SBP, DBP, and the HOMA score as
a marker of insulin resistance were all significantly higher in
the obese group.
Elevated levels of circulating HGF in obese subjects
correlate with BMI. As shown in Figure 1, obese subjects
had significantly higher serum HGF levels than lean sub-
jects (2,462  184 pg/ml vs. 765  48 pg/ml, p  0.0001
by t test with correction for unequal variances). Serum
VEGF levels, on the other hand, were not significantly
elevated in obese versus lean subjects (135  31 pg/ml vs.
128  37 pg/ml, p  NS by t test).
Circulating HGF levels were significantly correlated with
BMI (r  0.74; p  0.0001) (Fig. 2). On the other hand,
circulating VEGF levels did not show any significant
correlation with BMI (r  0.18, p  NS).
Lack of correlation between circulating HGF levels and
insulin resistance. Because increased insulin resistance is
associated with obesity, we determined whether insulin
resistance correlated with the elevated HGF levels in obe-
sity. We subdivided the obese subjects into three groups
according to their degree of insulin resistance and found no
significant difference in mean HGF concentrations between
the three groups (p  0.34 by analysis of variance) (Fig.
3A). Instead, increasing insulin resistance, as assessed by the
HOMA score, showed a nonsignificant trend of lower
HGF concentrations in obese patients (Fig. 3B).
Obesity-related increases in circulating HGF levels are
independent of increases in BP. Linear regression analysis
between BP and HGF concentrations using all patients
showed no correlation between SBP and HGF levels (r 
0.1, p  NS) but did show a significant correlation between
DBP and HGF levels (r  0.46, p  0.0005). Because the
obese subjects had significantly elevated BP (Table 1), it was
not clear whether the observed obesity-related increases in
HGF concentrations were primarily related to hypertension,
which is known to be associated with increased HGF levels
(26).
Therefore, we excluded all subjects in the lean and obese
groups with either known hypertension or with elevated BP
at the time of the blood draw for serum HGF determina-
tion. The remaining obese subjects had a mean SBP of 124
 3 mm Hg and a DBP of 74 2 mm Hg, which were not
significantly different from the SBP and DBP of the
remaining lean subjects (pNS). After the exclusion of the
hypertensive subjects, HGF levels were still significantly
elevated in the obese subjects when compared with the lean
subjects (2,328  360 pg/ml vs. 782.9  51.36, p  0.0008
by t test with correction for unequal variances) (Fig. 4A).
Exclusion of the hypertensive subjects actually resulted in an
even stronger correlation of HGF concentrations with BMI
(p  0.0001, r  0.78) (Fig. 4B), thus suggesting that the
correlation was not mediated by hypertension. In this
normotensive population, DBP was no longer significantly
correlated with HGF levels (r  0.25, p  NS).
Ex vivo expression of HGF by human adipose tissue. To
determine whether freshly isolated human adipose tissue
Table 1. Subject Characteristics
Lean Obese p Value
Total number 21 44
Female/male 13/8 32/12 NS
Age (yrs) 36  3 39  2 NS
BMI (kg/m2) 21  0.5 48  1  0.0001
Systolic BP (mm Hg) 121  4 139  3 0.0055
Diastolic BP (mm Hg) 69  3 80  1 0.0009
HOMA score 2.3  0.1 5.3  0.6  0.0001
Patients with 1 LFT 2 2 NS
Known atherosclerosis 0 2 NS
ESRD 0 0 NS
Malignancy 0 0 NS
Characteristics of subjects in the two groups are presented as mean SEM. The third
column denotes statistical significance as assessed by the t test for continuous variables
or Fisher exact test for categorical variables. In the case of BMI and HOMA scores,
a t test with correction for unequal variances between the two groups was used. A
value of p  0.05 was considered not significant (NS).
BMI  body mass index; BP  blood pressure; ESRD  end-stage renal disease;
HOMA  Homeostatic Model Assessment; LFT  liver function tests.
Figure 1. Obesity was associated with significant elevations of circulating
hepatocyte growth factor (HGF) (A) but not of circulating vascular endothelial
growth factor (VEGF) (B) in obese subjects when compared with lean
subjects. Data are presented as mean SEM, and the analysis was performed
using a t test. A value of p  0.05 was considered not significant (NS).
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could express HGF and thus may contribute to the systemic
elevation of HGF in obese subjects, we separated adipocytes
from ASC and assessed HGF messenger ribonucleic acid
expression as well as secretion of HGF in culture. As shown
in Figure 5, adipocytes and ASC both express HGF
messenger ribonucleic acid, and the level of expression
appears to be lower than that of human liver tissue.
Furthermore, both adipocytes and ASC can secrete HGF in
culture and achieve biologically active HGF concentrations,
which are substantially higher than those found in the
conditioned media of endothelial cells (Fig. 5B).
DISCUSSION
Obesity and HGF. To our knowledge, this is the first
report of a systemic vascular growth factor elevation in obese
patients. Our results indicate that obesity is associated with
a more than three-fold increase in circulating HGF levels,
correlating with the BMI. Some of the obese subjects in our
study were hypertensive, and hypertension has been associ-
ated with elevated circulating HGF levels (26). However,
after exclusion of hypertensive subjects, circulating HGF
levels were even more highly correlated with BMI. Further-
more, this increase in HGF levels was independent of the
extent of insulin resistance. Therefore, our data suggest that
the systemic HGF elevation observed in obese patients is
primarily correlated with the extent of obesity rather than
other components of the metabolic syndrome such as
hypertension or insulin resistance.
One possible interpretation for the correlation between
BMI and HGF concentrations is that the increased pres-
ence of adipose tissue may be responsible for the observed
elevations in HGF levels. This is further supported by our
observation that specific cellular components of human
adipose tissue can secrete HGF ex vivo. The expression of
HGF appeared to be lower than that of liver tissue.
However, considering that adipose tissue is very abundant in
obese subjects, these data suggest that adipose tissue may
Figure 2. The serum levels of hepatocyte growth factor (HGF) (A) were
significantly correlated with body mass index (BMI) as determined by
linear regression analysis. To maintain the scale of the graph, three obese
patients with HGF concentrations in the 4,000 to 6,500 pg/ml range are
omitted from this graph. However, they are included in the statistical
analysis. Circulating vascular endothelial growth factor (VEGF) levels (B),
on the other hand, were not correlated with the degree of obesity. A value
of p  0.05 was considered not significant (NS). Open squares  lean
subjects; solid circles  obese subjects.
Figure 3. Obese patients were subdivided into three groups according to
their insulin sensitivity using a Homeostatic Model Assessment (HOMA)
score (normal insulin sensitivity with HOMA score 3; moderate insulin
resistance with HOMA score between 3 and 5; and severe insulin
resistance with HOMA score 5). The mean serum HGF levels of these
three groups did not differ significantly using analysis of variance (A).
There was also no significant correlation between the degree of insulin
resistance (HOMA score) and hepatocyte growth factor (HGF) concen-
trations (B). There was a nonsignificant trend toward lower HGF levels
with higher insulin resistance. A value of p  0.05 was considered not
significant (NS).
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substantially contribute to systemic HGF levels in obesity.
The serum levels of VEGF, on the other hand, were not
elevated in obese patients. Even though it has previously
been shown that adipose tissue can secrete VEGF (10), the
overall contribution of adipose tissue to systemic circulating
levels may be substantially greater for HGF than for VEGF.
HGF as a link between obesity and coronary artery
disease. The elevated concentrations of HGF observed in
our study are in the range in which HGF exerts its
angiogenic and mitogenic effects on endothelial cells as well
as its synergistic enhancement of VEGF effects (14). There
is no clear evidence yet that HGF can directly contribute to
the progression of atherosclerosis by plaque neovasculariza-
tion as has been shown for VEGF (11); however, the
similarity and synergy of angiogenic and mitogenic effects
with VEGF (14) suggest that this could be the case. In
addition to the known association of circulating HGF levels
with atherosclerotic disease (18–20), a recent study demon-
strated the presence of HGF in atherosclerotic plaques (27).
On the other hand, HGF is also seen as a significant
cardioprotective factor because of its potent angiogenic
properties (13,28) and because HGF can reduce restenosis
after balloon injury by enhancing re-endothelialization (29).
Our findings may also contribute to understanding the
previously described “obesity paradox” that obese patients
actually have reduced mortality after percutaneous coronary
intervention (30). The systemic elevation of HGF in obesity
might increase the progression of atherosclerosis by plaque
neovascularization, while at the same time reduce post-
percutaneous coronary intervention mortality by enhancing
re-endothelialization.
Study limitations and future directions. One limitation
of our study is that the findings are limited to demonstrating
an association between obesity and HGF concentrations,
but do not prove that HGF acts in a pro-atherogenic
manner in obese patients. Because HGF also has multiple
Figure 4. Because hypertension can affect hepatocyte growth factor (HGF)
levels and hypertension has a higher prevalence among obese subjects,
hypertension could act as a confounding factor. Therefore, we excluded all
subjects with either known hypertension or documented hypertension at
the time of blood draw (either systolic blood pressure 140 mm Hg or
diastolic blood pressure90 mm Hg). The difference in mean serum HGF
levels between the remaining obese and lean subjects continued to be highly
significant (A). Furthermore, the correlation between body mass index and
HGF levels was even stronger in this group of subjects (B). Open squares
 lean subjects; solid circles  obese subjects.
Figure 5. (A) The reverse transcription-polymerase chain reaction tech-
nique demonstrates that freshly isolated human adipocytes and non-
adipocyte adipose stromal cells (ASCs) express hepatocyte growth factor
(HGF). The expression appears to be less than that of liver tissue, when
comparable amounts of total deoxyribonucleic acid (see glyceraldehyde-3-
phosphate dehydrogenase as control) are used. (B) Adipocytes and ASCs
can also secrete HGF protein into conditioned media, and achieve
biologically active HGF concentrations in the media, which are substan-
tially higher than those of cultured human aortic endothelial cells
(HAECs).
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beneficial effects on the vasculature, the elevation of HGF in
obese patients may instead be a vasculoprotective and
cardioprotective response to subclinical atherosclerotic dis-
ease. Transgenic mouse models could be used in future
studies to explore the effects of HGF on the progression of
atherosclerosis.
Another limitation is that the obese subjects in our study
were extremely obese, and that less obese subjects may not
have such marked HGF elevations, although the linear
correlation between HGF and BMI would suggest that
patients with a BMI 30 kg/m2 would also demonstrate
significant HGF elevations. Owing to the nature of the
study, we were not able to discern whether increased caloric
intake and reduced physical activity, which are common in
obese patients, contributed to the elevated HGF levels.
Little is known about the effects of both exercise and caloric
intake on HGF levels, and this could be addressed in future
studies. Other related questions that can be investigated are
whether HGF elevation in obese patients can affect such
processes as therapeutic angiogenesis, tumor angiogenesis,
or proliferative diabetic retinopathy, and whether specific
inhibitors or modulators of HGF production and signaling
pathways might indeed serve as targets for vascular thera-
pies. Future studies may also identify additional humoral
growth factors with vascular activity, which are secreted by
adipose tissue ex vivo and systemically elevated in obese
patients. We believe these data, as well as future related
studies, will contribute to understanding the complex mech-
anisms that link obesity and cardiovascular disease.
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